Sanofi SA banner

Sanofi SA
PAR:SAN

Watchlist Manager
Sanofi SA Logo
Sanofi SA
PAR:SAN
Watchlist
Price: 81.99 EUR 1.04% Market Closed
Market Cap: €100B

Sanofi SA
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sanofi SA
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Sanofi SA
PAR:SAN
Total Equity
€71.4B
CAGR 3-Years
-2%
CAGR 5-Years
2%
CAGR 10-Years
2%
Ipsen SA
PAR:IPN
Total Equity
€4.3B
CAGR 3-Years
9%
CAGR 5-Years
15%
CAGR 10-Years
13%
Vetoquinol SA
PAR:VETO
Total Equity
€567.4m
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
7%
Virbac SA
PAR:VIRP
Total Equity
€1.1B
CAGR 3-Years
10%
CAGR 5-Years
13%
CAGR 10-Years
10%
Boiron SA
PAR:BOI
Total Equity
€369.1m
CAGR 3-Years
-12%
CAGR 5-Years
-5%
CAGR 10-Years
0%
Medincell SA
PAR:MEDCL
Total Equity
-€30.6m
CAGR 3-Years
-6%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SAN Intrinsic Value
115.28 EUR
Undervaluation 29%
Intrinsic Value
Price

See Also

What is Sanofi SA's Total Equity?
Total Equity
71.4B EUR

Based on the financial report for Dec 31, 2025, Sanofi SA's Total Equity amounts to 71.4B EUR.

What is Sanofi SA's Total Equity growth rate?
Total Equity CAGR 10Y
2%

Over the last year, the Total Equity growth was -8%. The average annual Total Equity growth rates for Sanofi SA have been -2% over the past three years , 2% over the past five years , and 2% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett